# Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

> **NCT05868174** · PHASE1 · RECRUITING · sponsor: **Telix Pharmaceuticals (Innovations) Pty Limited** · enrollment: 36 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Advanced Solid Tumor
- Advanced Renal Cell Carcinoma

## Interventions

- **DIAGNOSTIC_TEST:** 89Zr-TLX250
- **COMBINATION_PRODUCT:** 177Lu-TLX250 and Peposertib

## Key facts

- **NCT ID:** NCT05868174
- **Lead sponsor:** Telix Pharmaceuticals (Innovations) Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-23
- **Primary completion:** 2024-12
- **Final completion:** 2026-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05868174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05868174, "Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05868174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*